Enfusion, Inc. (NYSE:ENFN) Short Interest Up 27.9% in January

Enfusion, Inc. (NYSE:ENFN - Get Free Report) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 711,700 shares, a growth of 27.9% from the December 31st total of 556,500 shares. Approximately 1.5% of the shares of the stock are sold short. Based on an average trading volume of 695,500 shares, the short-interest ratio is presently 1.0 days.

Insider Activity

In other news, CFO Bradley Herring sold 4,134 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $41,877.42. Following the transaction, the chief financial officer now directly owns 266,369 shares of the company's stock, valued at $2,698,317.97. The trade was a 1.53 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Oleg Movchan sold 2,771 shares of the company's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the sale, the chief executive officer now owns 526,702 shares of the company's stock, valued at approximately $5,335,491.26. This represents a 0.52 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 57,367 shares of company stock worth $591,335. Insiders own 36.44% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. New York State Common Retirement Fund boosted its position in Enfusion by 23.8% in the fourth quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company's stock valued at $19,848,000 after buying an additional 370,498 shares in the last quarter. Geode Capital Management LLC boosted its position in Enfusion by 7.3% in the third quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company's stock valued at $9,770,000 after buying an additional 70,367 shares in the last quarter. Wellington Management Group LLP boosted its position in Enfusion by 6.7% in the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company's stock valued at $9,265,000 after buying an additional 61,032 shares in the last quarter. State Street Corp boosted its position in Enfusion by 2.3% in the third quarter. State Street Corp now owns 952,895 shares of the company's stock valued at $9,043,000 after buying an additional 21,729 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its holdings in shares of Enfusion by 31.5% during the fourth quarter. Impax Asset Management Group plc now owns 890,000 shares of the company's stock worth $9,167,000 after purchasing an additional 213,052 shares during the period. 81.05% of the stock is owned by institutional investors.

Enfusion Stock Down 0.0 %

Shares of ENFN traded down $0.01 during mid-day trading on Wednesday, hitting $11.19. 615,794 shares of the company's stock were exchanged, compared to its average volume of 1,167,094. Enfusion has a 52 week low of $7.74 and a 52 week high of $11.38. The stock's 50-day simple moving average is $10.59 and its 200-day simple moving average is $9.48. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of 279.69, a price-to-earnings-growth ratio of 1.82 and a beta of 0.96.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ENFN shares. Piper Sandler increased their price objective on shares of Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research note on Monday, December 23rd. Stifel Nicolaus increased their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. Finally, William Blair reissued a "market perform" rating on shares of Enfusion in a report on Monday, January 13th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $10.50.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.